GE Healthcare B.V.

Simris Biologics Appoints ADC Expert Professor Andreas Pahl as CEO to Advance Microcystin Payload Platform

- Professor Andreas Pahl, former CEO of Heidelberg Pharma, has been appointed Chief Executive Officer of Simris Biologics GmbH, effective immediately. - Pahl brings over 25 years of ADC development experience, including leading Heidelberg Pharma's amanitin-based ADC platform into Phase I clinical validation. - He will focus on maximizing the value of Simris' differentiated Microcystin ADC payload platform and accelerating programs toward clinical development. - The company expects up to €1 million in gross proceeds from a warrant exercise to fund in vivo safety and efficacy studies for microcystin payload candidates.